Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Allergy Therapeutics Clear all
Recruiting Phase 4 Interventional

Menopausal HT for Women Living With HIV (HoT)

NCT06856174
View directory record Official record
Conditions
HIV Infection, Menopause
Interventions
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 2, 2026, 7:02 AM EDT
Completed No phase listed Observational

Biomarkers to Predict Time to Plasma HIV RNA Rebound

NCT03001128
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Antiretroviral treatment pause
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 2, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

NCT04243551
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug · Other
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205
View directory record Official record
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

NCT01928927
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Telmisartan
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed No phase listed Observational Results available

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

NCT00851799
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 2, 2026, 7:02 AM EDT
Completed No phase listed Observational

Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

NCT01029249
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 2, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional Results available

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

NCT02605304
View directory record Official record
Conditions
HIV-1 Infection, Hepatitis C
Interventions
Ledipasvir/sofosbuvir, Ribavirin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00104377
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
Overland Park, Kansas • North Dartmouth, Massachusetts • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Results available

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

NCT02128217
View directory record Official record
Conditions
HIV-1 Infection, Hepatitis
Interventions
Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

NCT01505114
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

NCT05476497
View directory record Official record
Conditions
Peanut Allergy
Interventions
VLP Peanut, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

NCT01403051
View directory record Official record
Conditions
HIV-1 Infection
Interventions
EFV/FTC/TDF, Calcium Carbonate, Vitamin D3, Placebo for calcium carbonate, Placebo for vitamin D3
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 2, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional Results available

Telephone Support to Improve Adherence to Anti-HIV Medications

NCT00988442
View directory record Official record
Conditions
HIV Infections
Interventions
Enhanced nursing telephone support, Standard care
Behavioral
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

NCT00417573
View directory record Official record
Conditions
IgG Deficiency, Infections
Interventions
IV Gamunex 10%
Drug
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 1, 2007 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

NCT00537394
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Raltegravir, Darunavir, Tipranavir, Etravirine, Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
61
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
42
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 2, 2026, 7:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Consent for Use of Stored Patient Specimens for Future Testing

NCT00031408
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
Not listed
Enrollment
17,444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2027
U.S. locations
62
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Levonorgestrel (LNG)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

NCT01777997
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

NCT02557633
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Neptune City, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 2, 2026, 7:02 AM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of SAR441236

NCT03705169
View directory record Official record
Conditions
HIV-1-infection
Interventions
SAR441236, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

NCT00096850
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Atazanavir, Rifampin, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
3
States / cities
Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 2, 2026, 7:02 AM EDT